Cardiovascular Research

CTLA4-Ig prolongs graft survival specifically in young but not old mice.

Authors: Timm Heinbokel|||Markus Quante|||Jasper Iske|||Yeqi Nian|||Ryoichi Maenosono|||Koichiro Minami|||Yang Liu|||Haruhito Azuma|||Abdallah Elkhal|||Stefan G Tullius

Affiliations: + Expand

Abstract

Elderly organ transplant recipients have remained underrepresented in clinical trials, despite representing a rapidly growing population. Here, we assessed age-specific effects of CTLA4-Ig (cytotoxic T-lymphocyte antigen 4-Ig), a fusion protein blocking costimulatory signaling between antigen-presenting cells and T cells through CD28. Cardiac allografts in young mice (2-3 months) treated with CTLA4-Ig survived indefinitely, whereas 80% of old recipients (18 months) had lost their graft after 100 days. CTLA4-Ig was also significantly less effective in older recipients of skin transplants. CTLA4-Ig reduced CD4 central memory and effector memory T cells and diminished systemic interferon-gamma levels only in young recipients. These differences corresponded to a reduced expression of CD28 on antigen-experienced CD4 T cells in old mice. In support, adoptive transfer of old CD4 T cells that were transfected with a lentiviral vector inducing constant expression of CD28 accelerated the rejection of allogeneic skin grafts in young RAG2 recipient mice. Regulatory T cells (Tregs), in contrast, demonstrated an increased expression of CD28 with aging and CTLA4-Ig treatment in old recipients resulted in reduced frequencies, compromised proliferation, and diminished suppressive capacity of Tregs. These findings may prove to have unique clinical consequences for immunosuppression in the growing population of elderly transplant recipients.

---

Chemical List

CD28 Antigens|||CTLA-4 Antigen|||Immunoconjugates|||Abatacept

---

Reference List

Annual Data Report of the US Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR). Preface. Am J Transplant 2013;13 Suppl 1:1–7.|||Martins PN, Tullius SG, Markmann JF. Immunosenescence and immune response in organ transplantation. Int Rev Immunol 2014;33(3):162–173.|||Fagnoni FF, Vescovini R, Mazzola M, Bologna G, Nigro E, Lavagetto G et al. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology 1996;88(4):501–507.|||Mou D, Espinosa J, Lo DJ, Kirk AD. CD28 negative T cells: is their loss our gain? Am J Transplant 2014;14(11):2460–2466.|||Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev 2006;127(3):274–281.|||Murasko DM, Weiner P, Kaye D. Decline in mitogen induced proliferation of lymphocytes with increasing age. Clin Exp Immunol 1987;70(2):440–448.|||Bernstein ED, Murasko DM. Effect of age on cytokine production in humans. Age (Omaha) 1998;21(4):137–151.|||Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999–2008. Am J Transplant 2010;10(4 Pt 2):961–972.|||Heinbokel T, Elkhal A, Liu G, Edtinger K, Tullius SG. Immunosenescence and organ transplantation. Transplant Rev (Orlando) 2013;27(3):65–75.|||Karim A, Farrugia D, Cheshire J, Mahboob S, Begaj I, Ray D et al. Recipient age and risk for mortality after kidney transplantation in England. Transplantation 2014;97(8):832–838.|||Bradley BA. Rejection and recipient age. Transpl Immunol 2002;10(2–3):125–132.|||Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005;56(1):23–46.|||Blosser CD, Huverserian A, Bloom RD, Abt PD, Goral S, Thomasson A et al. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation 2011;91(8):858–863.|||Prescription Drugs: FDA Guidance and Regulations Related to Data on Elderly Persons in Clinical Drug Trials. GAO-07–47R. US Government Accountability Office 2007.|||Beyersdorf N, Kerkau T, Hünig T. CD28 co-stimulation in T-cell homeostasis: a recent perspective. Immunotargets Ther 2015;4:111–122.|||Alegre ML, Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des 2006;12(2):149–160.|||Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10(3):535–546.|||Fellström B, Jardine AG, Soveri I, Cole E, Grönhagen-Riska C, Neumayer HH et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005;79(9):1160–1163.|||Denecke C, Bedi DS, Ge X, Kim IK, Jurisch A, Weiland A et al. Prolonged graft survival in older recipient mice is determined by impaired effector T-cell but intact regulatory T-cell responses. PLoS One 2010;5(2):e9232.|||Krenzien F, Quante M, Heinbokel T, Seyda M, Minami K, Uehara H et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. Am J Transplant 2017;17(5):1242–1254.|||Bedi DS, Krenzien F, Quante M, Uehara H, Edtinger K, Liu G et al. Defective CD8 Signaling Pathways Delay Rejection in Older Recipients. Transplantation 2016;100(1):69–79.|||Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010;28:445–489.|||Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood 2003;101(9):3543–3549.|||Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68(5):855–867.|||Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol 2008;181(4):2285–2291.|||Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003;171(7):3348–3352.|||Zhou Z, Shen J, Hong Y, Kaul S, Pfister M, Roy A. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther 2012;92(2):251–257.|||Xu H, Perez SD, Cheeseman J, Mehta AK, Kirk AD. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. Am J Transplant 2014;14(2):319–332.|||Vallejo AN, Nestel AR, Schirmer M, Weyand CM, Goronzy JJ. Aging-related deficiency of CD28 expression in CD4+ T cells is associated with the loss of gene-specific nuclear factor binding activity. J Biol Chem 1998;273(14):8119–8129.|||Monteiro J, Batliwalla F, Ostrer H, Gregersen PK. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996;156(10):3587–3590.|||Borthwick NJ, Lowdell M, Salmon M, Akbar AN. Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol 2000;12(7):1005–1013.|||Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, Birch KE, Cook JE, Jackson SE et al. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol 2005;175(12):8218–8225.|||Weng NP, Akbar AN, Goronzy J. CD28(−) T cells: their role in the age-associated decline of immune function. Trends Immunol 2009;30(7):306–312.|||Tullius SG, Milford E. Kidney allocation and the aging immune response. N Engl J Med 2011;364(14):1369–1370.|||Bryl E, Vallejo AN, Weyand CM, Goronzy JJ. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001;167(6):3231–3238.|||Wakikawa A, Utsuyama M, Hirokawa K. Altered expression of various receptors on T cells in young and old mice after mitogenic stimulation: a flow cytometric analysis. Mech Ageing Dev 1997;94(1–3):113–122.|||de Graav GN, Hesselink DA, Dieterich M, Kraaijeveld R, Weimar W, Baan CC. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. PLoS One 2016;11(2):e0148604.|||Cortes-Cerisuelo M, Laurie SJ, Mathews DV, Winterberg PD, Larsen CP, Adams AB et al. Increased Pretransplant Frequency of CD28(+) CD4(+) T(EM) Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients. Am J Transplant 2017;17(9):2350–2362.|||Effros RB. Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol 1997;21(6):471–478.|||Maly K, Schirmer M. The story of CD4+ CD28- T cells revisited: solved or still ongoing? J Immunol Res 2015;2015:348746.|||Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001;193(10):1159–1167.|||Zal B, Kaski JC, Akiyu JP, Cole D, Arno G, Poloniecki J et al. Differential pathways govern CD4+ CD28- T cell proinflammatory and effector responses in patients with coronary artery disease. J Immunol 2008;181(8):5233–5241.|||Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998;41(12):2108–2116.|||Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002;105(5):570–575.|||Zhang X, Fujii H, Kishimoto H, LeRoy E, Surh CD, Sprent J. Aging leads to disturbed homeostasis of memory phenotype CD8(+) cells. J Exp Med 2002;195(3):283–293.|||Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Front Immunol 2019;10:43.|||Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005;6(2):152–162.|||Riella LV, Liu T, Yang J, Chock S, Shimizu T, Mfarrej B et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant 2012;12(4):846–855.|||Charbonnier LM, Vokaer B, Lemaître PH, Field KA, Leo O, Le Moine A. CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells. Am J Transplant 2012;12(9):2313–2321.|||Sun L, Hurez VJ, Thibodeaux SR, Kious MJ, Liu A, Lin P et al. Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. Aging Cell 2012;11(3):509–519.